Adia Nutrition Inc (OTC: ADIA) is a biologic products company (SIC 2836) that develops and sells umbilical cord stem cell treatments, biologic products, and nutritional supplements. Revenue comes from the sale of supplements, medical procedures, biologic products, ancillary products, shipping, and sublease income. The company operates Adia Med of Winter Park, LLC as its clinical treatment facility and Adia Labs, LLC as its biologic product procurement and sales arm. Revenues were $700,508 for the year ended December 31, 2025, compared to $6,380 for the year ended December 31, 2024. The company was revived under Nevada charter in June 2022 following a custodianship proceeding, with Nikki Lee appointed as sole officer and director at that time. The company filed one provisional patent in 2025 and holds trademarks on two products. ADIA operates at an early commercial stage with net losses reported in each disclosed period.

Revenue model

Transactional revenue from the sale of supplements, medical procedures, biologic products, ancillary products, shipping and delivery, other services, and sublease income. No subscription or royalty revenue model is disclosed in the 10-K filed March 31, 2026.

Products and services

Umbilical Cord Blood Stem Cell (UCB-SC) treatments marketed as AdiaVita, containing at least 100 million stem cells and 3 trillion exosomes per unit. Products registered with the FDA under Section 361 of the Public Health Service Act (PHSA) and 21 CFR Part 1271. Treatments address orthopedic issues, pain management, and wound repair. The company also sells nutritional supplements. One provisional patent was filed in 2025.

Customers and end markets

Healthcare providers and health insurance companies are the stated partnership targets. End markets include regenerative medicine, orthopedics, pain management, and wound repair. No customer concentration data or customer counts are disclosed in the filing.

Value-chain role

ADIA sources raw amniotic fluid and cord material from FDA-approved, AABB-accredited cord-blood banks within the United States. Manufacturing is performed under cGMP conditions in an ISO7 clean room. Release testing is conducted by independent third-party labs. The company operates its own clinical treatment locations and sells biologic products through Adia Labs, LLC.

Geographic exposure

Operations based in Winter Park, Florida, with a stated plan for a nationwide rollout of satellite clinic locations. No international operations are disclosed in the filing.

Source: SEC 10-K, filed 2026-03-31

Industry: Medicinal Chemicals & Botanical Products